We have demonstrated for the first time the ability of the ChAdOx1–MVA vaccination strategy to induce strong sustained CD8+ T-cell responses to the tumour-specific self-antigen STEAP1 in murine models. This evidence concerns the gene STEAP1 and neoplasm.